2McQuarrie EP, Stirling CM, Geddes CC. Idiopathic membranous nephropathy and nephrotic syndrome outcome in the era of evidence-based therapy[J]. Nephrol Dial Transplant, 2012,2 (7) : 235 - 242.
3Quaglia M, Stratta P. Idiopathic membranous ne- phropathy: management strategies [J].Drugs, 2009, 69(10) : 1303-1317.
4Ji SM, Li LS, Sha GZ, et al. Conversion from cy- closporine to tacrolimus for chronic allograft ne- phropathy[J]. Transplant Proc, 2007, 39(5) :1402 -1405.
5Bowman L J, Brennan DC. The role of tacrolimus in renal transplantation [J].Expert Opin Pharmacoth- er,2008, 9(4) :635-643.
6Ponticelli C, Zucchelli P, Passerini P, et al. A 10- year follow-up of a randomized study with methyl- prednisolone and chlorambucil in membranous ne- phropathy[J]. Kidney Int, 1995, 48(S):1600- 1604.
7Ruggenenti P, Cravedi P, Remuzzi G. Latest treat- ment strategies for membranous nephropathy[J]. Expert Opin Pharmacother, 2007, 8 (18) : 3159 - 3171.
8Ruggenenti P, Cravedi P, Remuzzi G. Latest treat ment strategies for membranous nephropathy [J]. Expert Opin Pharmacother, 2007, 8 (18) : 3159 - 3171.
9Aaltonen S, Honkanen E. Outcome of idiopathic membranous nephropathy using targeted stepwise immunosuppressive treatment strategy[J]. Nephrol Dial Transplant, 2011,26(9) :2871-2877.
10Takahashi S, Hiromura K, Sakurai N, et al. Effi- cacy and safety of tacrolimus for induction therapy in patients with active lupus nephritis [J]. Mod Rheumatol, 2011,21(3) :282-289.
